You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES
NEWS / EVENTS / .........

EVENTS - 15-04-2021

World Hemophilia Day 2021, Kedrion alongside patients

On the occasion of World Hemophilia Day 2021, which will be celebrated worldwide on April 17, 2021 and which, for the second year running, will take place in the COVID-19 pandemic, Kedrion Biopharma is proud to convey its closeness – across and beyond physical distances - to patients, their families and their associations.

The theme chosen by the World Federation of Hemophilia (WFH) is "Adapting to change - Sustaining care in a new world," to illustrate the need to adapt to a continuously changing and rapidly evolving world, marked by new social, environmental and developmental challenges that will closely impact the global health ecosystem and the daily lives of patients.

In Italy, Kedrion has paid tribute to this anniversary by supporting the event entitled "Chronically rare: resources must be pursued," scheduled on April 15 in live streaming at the Sala Mastai of the Palazzo dell'Informazione in Rome and organized by the Italian Federation of Hemophilia Societies (FedEmo) together with the Italian Association of Hemophilia Centers (AICE) and the Paracelsus Foundation, under the patronage of the Italian Ministry of Health. The round table will analyze and discuss all aspects relating to possible demedicalization in Italy; starting from the creation of synergies leading to existing community nursing services, and with the support of innovative health technologies such as telemedicine, the aim is to organize and manage at local level system approach which essentially should be shared at national level.

The difficulties brought on by by the pandemic have not prevented us from continuing to guarantee our support to patient associations and to the medical-scientific community. In Italy, this commitment has resulted in offering support to varied initiatives aimed at promoting an ever greater centrality and participation of patients, including: the "Words in Hemophilia: Towards Patient Engagement" project, currently underway at the "EngageMinds HUB" Research Center of the Università Cattolica del Sacro Cuore in Milan; and #KoalaACasaTua, a home delivery service for medicines distributed by Kedrion for the treatment of Hemophilia which has been operating since April 2020 with the aim of safeguarding the health of the more vulnerable

In Turkey, where Kedrion has consolidated its direct presence in recent years, we continue our commitment alongside the local medical community to improve knowledge and awareness in the field of coagulation disorders, by focusing the discussion on the role of replacement therapy in the treatment of Hemophilia A.

In the rest of Europe and worldwide, for several years now we have been supporting the PARTNERS project promoted by the European Hemophilia Consortium (EHC) and, at the same time, we have been supporting the World Federation of Hemophilia (WFH) in order to improve access to treatment for coagulation disorders,

With the same goal in mind, Kedrion continues to work alongside the Italian National Blood Center (CNS) and several Italian Regions on ethical, transparent projects to support disadvantaged countries, which in 2020 included Albania, Afghanistan, Armenia, El Salvador and - most recently - Palestine.

For more information please contact: [email protected]